Naratriptan Ratiopharm

Naratriptan, the active ingredient in Naratriptan Ratiopharm, is a Triptan presented as a tablet for oral use. It treats acute migraine attacks in adults.

GNH USA supplies Naratriptan Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan is a Triptan indicated for the acute treatment of migraine.

Migraine without aura: provides rapid relief of headache pain and associated symptoms when taken at the onset of an attack. Migraine with aura: reduces the severity of headache and associated nausea when administered early. Acute migraine attacks: helps abort the migraine episode and improve functional ability during the attack.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient feeling of light‑headedness. - Drowsiness: occasional fatigue or sleepiness. - Dry mouth: reduced salivation. - Tingling sensations: paresthesia in extremities. - Fatigue: general lack of energy.

Serious or Rare Side Effects: - Chest pain: possible cardiac ischemia. - Severe hypertension: sudden rise in blood pressure. - Serotonin syndrome: agitation, hyperthermia, tremor. - Allergic reactions: rash, swelling, anaphylaxis. - Arrhythmias: irregular heart rhythm. - Myocardial infarction: rare heart attack events.

Before using Naratriptan, consider the following precautions.

Cardiovascular disease: avoid if you have coronary artery disease, angina, or history of myocardial infarction. Uncontrolled hypertension: do not use if blood pressure is not well managed. Liver impairment: use with caution in moderate to severe hepatic dysfunction. Concomitant MAO inhibitors: avoid simultaneous use due to risk of serotonin toxicity. Pregnancy and lactation: only use if benefits outweigh potential risks. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with several medicines.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: increase serotonin toxicity. - Ergot alkaloids: additive vasoconstriction may cause ischemia. - Other triptans: cumulative vasoconstrictive effect. - Strong CYP1A2 inhibitors: may raise naratriptan plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible reduction in blood pressure control. - Oral contraceptives: may alter hormonal efficacy. - CYP3A4 inhibitors (e.g., ketoconazole): modest increase in exposure. - Antihistamines: may enhance drowsiness. - Diuretics: monitor electrolytes and blood pressure.